119584-81-5

Basic information

• Product Name: 2,4-Quinazolinediamine,5-ethoxy-(9CI)
• Synonyms: 2,4-Quinazolinediamine,5-ethoxy-(9CI);5-ethoxy-2,4-quinazolinediamine
• CAS NO: 119584-81-5
• Molecular Formula: C10H12N4O
• Molecular Weight: 204.232
• Product Categories: ETHOXY
• Mol File: 119584-81-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 482.6°Cat760mmHg
• Flash Point: 245.7°C
• Appearance: /
• Density: 1.317g/cm³
• Vapor Pressure: 1.8E-09mmHg at 25°C
• Refractive Index: 1.701
• CAS DataBase Reference: 2,4-Quinazolinediamine,5-ethoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Quinazolinediamine,5-ethoxy-(9CI)(119584-81-5)
• EPA Substance Registry System: 2,4-Quinazolinediamine,5-ethoxy-(9CI)(119584-81-5)

Safety Data

• Hazardous Substances Data: 119584-81-5(Hazardous Substances Data)

Usage

Chemical structure

Quinazoline ring with an amino group at positions 2 and 4, and an ethoxy group at position 5

Classification

Organic compound, belongs to the quinazoline family

Potential applications

Medicinal chemistry, drug discovery

Possible properties

Biological activities, can be used as a building block in the synthesis of other organic compounds

Additional information

Further research is needed to fully understand its potential uses and properties.

InChI:InChI=1/C10H12N4O/c1-2-15-7-5-3-4-6-8(7)9(11)14-10(12)13-6/h3-5H,2H2,1H3,(H4,11,12,13,14)

Upstream product

• 123241-42-9 2-amino-6-ethoxybenzonitrile 
• 593-85-1 diguanidine carbonate 
• 35213-00-4 2,6-dinitrobenzonitrile 
• 1897-52-5 2,6 difluorobenzonitrile 
• 29671-92-9 chloroformamidine hydrochloride 
• 124-46-9 guanidine hydrogen carbonate 
• 119584-73-5 2-ethoxy-6-fluorobenzonitrile 
• 606-21-3 1-chloro-2,6-dinitrobenzene 
• 123241-32-7 2-ethoxy-6-nitro-benzonitrile 

Relevant articles and documents

USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS

Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.

Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors

The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC50 = 0.15 μM). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC50 = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.

Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: Structure-activity and structure-selectivity correlations

A structurally diverse library of 93 lipophilic di- and tricyclic diaminopyrimidine derivatives was tested for the ability to inhibit recombinant dihydrofolate reductase (DHFR) cloned from human and bovine isolates of Cryptosporidium parvum (J. R. Vasquez et al., Mol. Biochem. Parasitol. 79:153-165, 1996). In parallel, the library was also tested against human DHFR and, for comparison, the enzyme from Escherichia coli. Fifty percent inhibitory concentrations (IC50s) were determined by means of a standard spectrophotometric assay of DHFR activity with dihydrofolate and NADPH as the cosubstrates. Of the compounds tested, 25 had IC50s in the 1 to l0 μM range against one or both C. parvum enzymes and thus were not substantially different from trimethoprim (IC50s, ca. 4 μM). Another 25 compounds had IC50s of 50s of 50s, 50s of 50s of 0.3 μM and thus were comparable in potency to trimetrexate. The finding that submicromolar concentrations of several of the compounds in the library could inhibit in vitro growth of C. parvum in host cells in the presence of thymidine (dThd) and hypoxanthine (Hx) suggests that lipophilic DHFR inhibitors, in combination with leucovorin, may find use in the treatment of intractable C. parvum infections.